Recon Technology, Ltd. (NASDAQ:RCON) [Trend Analysis] try to make new thrust in street and making different trends, stocks trading ended with 7.59% to $1.56. Recon Technology, Ltd. (RCON) released that it has been awarded a patent for its proprietary Oilfield Wastewater Treatment Device by China’s State Intellectual Property Office.Oily wastewater, as the outcome of the oilfield exploitation process, contains water, various oils, chemical polymers, heavy metals, microorganisms, and suspended and dissolved solids.
The treatment of oilfield wastewater represents not only serious operational issues, but also a major environmental challenge to all oil producers. As a total solution provider to Chinese stated owned petroleum companies, Recon has developed the Oilfield Wastewater Treatment Device to improve the effectiveness of water treatment, reduce infrastructure investment and operating costs for oil companies.
The patented device can separate the sewage sludge and oil pollution from crude oil within one integrative equipment and at the same time, produce water that is qualified for direct discharge, reinjection or other oil-company projects, thus importantly increasing the processing effectiveness and cost-savings of wastewater treatment. In addition to this patent, the company is currently applying for several other patents designed to facilitate removal of toxic substances and metallic elements from wastewater. The share price of RCON attracts active investors, as stock price of week volatility recorded 26.63%. The stock is going forward to its 52-week low with 81.71% and lagging behind from its 52-week high price with -36.59%.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) [Trend Analysis] plunged reacts as active mover, shares a decrease -5.43% to traded at $35.03 and the percentage gap between open changing to regular change was -4.62%. Teva Pharmaceutical Industries Ltd. (TEVA) declared that it has received a positive outcome through the variation procedure to remove the pregnancy contraindication from the European label for COPAXONE (glatiramer acetate injection) 20 mg/mL. The product was originally authorized through a decentralized procedure in Europe.
The removal of the pregnancy contraindication follows a Positive Variation Assessment Report issued by the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA; Reference Member State), and agreed by all Concerned Member States (CMS) in Europe, that were involved in the procedure. Granting of national approvals by all involved EU Member States will happen in the near future. COPAXONE is indicated for the treatment of patients with relapsing forms of multiple sclerosis or RMS. The firm’s current ratio calculated as 0.90 for the most recent quarter. The firm past twelve months price to sales ratio was 1.80 and price to cash ratio remained 23.36. As far as the returns are concern, the return on equity was recorded as 5.70% and return on investment was 5.70% while its return on asset stayed at 2.40%. The firm has total debt to equity ratio measured as 1.17.